AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04700124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
Study NCT06249867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 MG Extended Release Oral Tablet
Description: During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.
Study NCT06249867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
Study NCT06373848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive 30 mg of Coq10
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
Study NCT04895956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-sheath injection
Description: Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
Study NCT05921032 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: 8 weeks of exercise with two session in a week
Study NCT04922268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internal focus of attention feedback
Description: Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
Study NCT04922268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention feedback
Description: Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
Study NCT04895956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-sheath injection
Description: Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
Study NCT04895956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
Study NCT04895956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
Study NCT06400121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apimostinel Infusion, Intravenous
Description: Single injection of Apimostinel (10mg)
Study NCT06400121 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Apimostinel Infusion, Intravenous
Description: Single injection of Apimostinel (10mg)
Study NCT06400121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 8 sessions of digital active training
Study NCT06400121 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: 8 sessions of digital active training
Study NCT06400121 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of digital sham training
Study NCT06400121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Solution, Intravenous
Description: Single injection of placebo
Study NCT06343792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
Study NCT05702047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nose-only breathing
Description: Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
Study NCT05702047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-only breathing
Description: Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
Study NCT05422794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT06373848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receive 30 mg of Coq10
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
Study NCT05422794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05422794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06418984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auxiliary
Description: the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
Study NCT04914273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation Spray
Description: 400 mcg salbutamol administered per metered dose inhaler
Study NCT04914273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 mg salbutamol administered per tablet for ingestion
Study NCT05071027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endovascular Neurosurgery
Description: Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
Study NCT05422794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05422794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05422794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05422794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05550727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PorchLight
Description: The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
Study NCT05611801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marstacimab
Description: marstacimab
Study NCT06433193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAK HD Sorbent Therapy
Description: Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful.
Study NCT05085392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: 6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
Study NCT06297408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
Study NCT05524948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice
Description: Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
Study NCT05524948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice
Description: Standard fluoride dentifrice containing 0.243% sodium fluoride.
Study NCT06642857 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood, tougue coating, saliva, and feces
Description: Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 25mg via HAI (Pre-chemotherapy)
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anisodamine
Description: 10 mg via HAI (Pre-chemotherapy)
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 via HAI over 3 hours
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2 via HAI
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 intravenously
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 intravenously
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 intravenously over 3 hours
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/m2 intravenously
Study NCT05727163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
Study NCT06116435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
Study NCT06070350 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low Titer Group O Whole Blood (LTOWB)
Description: LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
Study NCT06116435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move group-based classes
Description: The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
Study NCT06116435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Membership
Description: Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
Study NCT06116435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
Study NCT06070350 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be provided to the research pharmacy at each of the clinical sites
Study NCT06070350 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid (TXA)
Description: TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
Study NCT06070350 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Component Therapy (CT)
Description: Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
Study NCT06563752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participants will use 3D glasses to view VR educational information
Description: Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources.
Study NCT06563752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Description: Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
Study NCT05739162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Endoscopic Suture System
Description: Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
Study NCT05739162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
Study NCT06327256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202
Study NCT06327256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 3000202
Study NCT06116435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 1:1 Support
Description: Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
Study NCT06321627 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy as curative treatment
Description: Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
Study NCT06327256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT05860868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles induction chemotherapy
Description: Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study NCT05860868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 cycles induction chemotherapy
Description: Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study NCT05124236 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative radiosurgery
Description: single fraction radiosurgery
Study NCT05124236 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative hypofractionated stereotactic radiotherapy
Description: 5 fraction stereotactic radiotherapy /fractionated radiosurgery
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: noF-noRAS
Description: resting state, that is, without finger-tapping and without listening to RAS
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: F-noRAS
Description: finger-tapping without listening to RAS
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: noF-100RAS
Description: listening to RAS with the 100% of the baseline tempo and without finger-tapping
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: F-100RAS
Description: finger-tapping and listening to RAS with 100 % of baseline tempo
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: F-105RAS
Description: finger-tapping and listening to RAS with 105 % of baseline tempo
Study NCT05839821 — intervention group
Intervention type: BEHAVIORAL
Intervention: F-110RAS
Description: finger-tapping and listening to RAS with 110 % of baseline tempo
Study NCT06164197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Robot Assisted Gait Training
Study NCT04576936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIRVO
Description: Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
Study NCT04721145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitor
Description: Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
Study NCT06377007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOLMaster 700 (Carl Zeiss Meditec AG)
Description: Subjects will undergo measurements with the IOLMaster 700 device.
Study NCT06377007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argos (Alcon Laboratories, Inc.)
Description: Subjects will undergo measurements with the Argos device.
Study NCT04878211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by monthly administrations